Ligand Pharmaceuticals (LGND) investor relations material

Executive summary

• Q3 royalty revenue rose 51% YoY to $70.3 million, supported by XOMA-acquired assets and momentum in Filspari and Ohtuvayre.

• XOMA expanded the portfolio to more than 200 royalty assets, adding seven commercial products, 14 late-stage programs and more than 100 other development assets.

• FY2026 adjusted diluted EPS guidance increased to $9.50–$9.75; total revenue guidance was reaffirmed at $270–$310 million.

Financial highlights

• Q3 total revenue and income were $78.7 million, down 32% YoY; excluding $53.1 million of prior-year Pelthos income, they increased 26%.

• Core revenue was $78.7 million, down 9% YoY; excluding the $24.5 million prior-year ZELSUVMI out-license fee, core revenue grew 26%.

• GAAP net loss was $28.5 million, or $1.43 per diluted share, versus net income of $117.3 million, or $5.68; Q3 included $39.5 million of pretax investment losses.

• Adjusted net income was $57.5 million, or $2.67 per diluted share, versus $63.8 million, or $3.09, in Q3 2025.

• G&A was $72.6 million, up $44.2 million YoY; costs included acquisition expenses, post-combination compensation, severance and higher credit-loss allowances.

Outlook and guidance

• FY2026 guidance: royalty revenue $225–$250 million; total revenue $270–$310 million; Captisol revenue $35–$40 million; contract revenue $10–$20 million.

• Adjusted diluted EPS guidance rose to $9.50–$9.75 from $9.00–$9.50; revenue is expected to be more heavily weighted to Q4.

• Q4 includes a full quarter of XOMA royalties and potential higher tiered royalty rates; management expressed confidence in reaching the mid-to-high end of royalty guidance or exceeding it.

• Captisol orders, partner reporting, milestones and clinical or regulatory events may shift timing; an updated five-year outlook is planned for the December 8 Investor Day.